Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NewAmsterdam Pharma Company N.V. - Ordinary Shares
(NQ:
NAMS
)
22.94
-1.22 (-5.05%)
Delayed Quote
Updated: 1:01 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about NewAmsterdam Pharma Company N.V. - Ordinary Shares
< Previous
1
2
3
4
Next >
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
September 29, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
September 21, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
September 02, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
August 26, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 05, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
July 29, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
July 24, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
July 01, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
June 03, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
May 28, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
May 11, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
May 07, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
March 23, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
February 25, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
February 18, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
February 04, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
January 09, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
November 25, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
November 05, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
October 30, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
September 24, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
